MAT for Veterans: How Suboxone, Vivitrol, and Campral Work

In 2019, the VA issued a system-wide directive mandating that all VA facilities offer medication-assisted treatment for opioid use disorder. The directive came after years of VA facilities refusing to provide buprenorphine, the most evidence-backed opioid treatment medication, citing concerns about substituting one drug for another. That institutional stigma cost Veterans lives. Research published in JAMA Internal Medicine found that veterans with opioid use disorder who received buprenorphine treatment had a 50 percent reduction in overdose mortality compared to those who received no medication. The science was never in question. The barrier was stigma, and it took a federal mandate to overcome it inside the VA system.

What MAT Is, and Why the Stigma Is Wrong

Medication-assisted treatment is the use of FDA-approved medications, in combination with counseling and behavioral therapies, to treat substance use disorders. For opioid use disorder, the primary medications are buprenorphine (commonly prescribed as Suboxone), methadone, and naltrexone (Vivitrol). For alcohol use disorder, the evidence-supported medications include naltrexone, acamprosate (Campral), and disulfiram (Antabuse).

The central objection to MAT, that it replaces one drug with another, fundamentally misunderstands what addiction is. Opioid use disorder is not a failure of character or willpower. It is a chronic neurobiological condition involving lasting changes to dopamine signaling, mu-opioid receptor density, and the brain’s stress response systems. SAMHSA describes MAT as treating the whole patient: addressing the biological substrate of addiction while behavioral therapies address the psychological and social dimensions.

For veterans, the stigma around MAT carries particular weight. Military culture prizes self-reliance and views seeking help as weakness. Accepting a medication to manage substance use can feel like admitting defeat twice over. This is a category error. A veteran with diabetes who takes insulin is not failing to manage their blood sugar through willpower. A veteran with opioid use disorder who takes buprenorphine is not failing to achieve sobriety; they are treating a medical condition with an evidence-based medication.

Hope Valley Health and Wellness’s clinical team encounters this stigma regularly. The clinical work of addressing it begins in the first intake assessment, continues through psychoeducation in the residential program, and is reinforced by a peer community in which veterans on MAT are not separated from those managing other treatment protocols. Recovery is not defined by the absence of medication; it is defined by restored function, improved health, and rebuilt relationships.

For an overview of how substance use disorders develop in the Service member population, see our resource on Veteran opioid addiction.

Buprenorphine and Suboxone: How They Stop Opioid Cravings

Buprenorphine is a partial opioid agonist: it binds to the same mu-opioid receptors that heroin and fentanyl bind to, but it activates them only partially. This partial activation produces two clinically critical effects: it prevents withdrawal symptoms and craving, and it has a ceiling effect on respiratory depression that makes it substantially safer than full agonists at high doses.

Suboxone is the most commonly prescribed formulation: a film or tablet containing buprenorphine combined with naloxone. The naloxone component is poorly absorbed sublingually (under the tongue) but becomes active if the medication is injected, precipitating immediate withdrawal in an opioid-dependent person. This combination makes diversion and misuse significantly less likely.

The mechanism of action is straightforward. When a person dependent on opioids is in withdrawal, their opioid receptors are unoccupied and firing stress signals, producing the sweating, cramping, anxiety, insomnia, and intense craving characteristic of opioid withdrawal. Buprenorphine occupies those receptors sufficiently to silence the withdrawal signal without producing significant euphoria. Over time, with stable buprenorphine dosing, the receptor system normalizes and craving diminishes.

Critically, buprenorphine’s high receptor affinity means that if a person on a therapeutic buprenorphine dose uses heroin or fentanyl, the buprenorphine blocks those substances from binding to receptors, preventing any reinforcing effect. This pharmacological blockade substantially reduces the incentive to use during treatment and decreases relapse rates.

A clinical consideration specific to fentanyl: because fentanyl is highly fat-soluble, it accumulates in body tissues and releases slowly. Veterans dependent on fentanyl require longer periods of pre-induction withdrawal before buprenorphine can be safely started without triggering precipitated withdrawal. Hope Valley’s clinical team manages this induction process with medical supervision, using validated withdrawal assessment tools to determine optimal timing.

Research consistently demonstrates that longer duration of buprenorphine treatment produces better outcomes. Studies published in NEJM document that patients maintained on buprenorphine for 12 months or more have significantly lower rates of illicit opioid use and overdose compared to those who discontinue after 30–90 days. For veterans with chronic trauma histories and years of substance use, long-term maintenance is frequently the appropriate clinical plan.

Vivitrol (Naltrexone): The Shot That Blocks the Effect

Naltrexone is an opioid antagonist: it binds to mu-opioid receptors with high affinity and blocks them completely, preventing any opioid from producing effect. Unlike buprenorphine, which activates receptors partially, naltrexone produces no opioid effect whatsoever. It works as a pure blocker.

The clinical implication is significant: a veteran who uses heroin or fentanyl while on naltrexone will experience no euphoria, no pain relief, and no reduction in craving from the opioid. The behavioral reinforcement that sustains addiction is pharmacologically eliminated. Over time, without positive reinforcement, drug-seeking behavior extinguishes.

The critical constraint with naltrexone is that it must be initiated after complete detoxification. Because naltrexone competes with opioids for receptor binding, administering it to a person who is still opioid-dependent will immediately precipitate severe withdrawal, a dangerous and acutely painful syndrome. Patients must be fully opioid-free, typically for 7–10 days following last use of short-acting opioids and longer following methadone or fentanyl, before naltrexone can be safely started.

Vivitrol is the extended-release injectable formulation of naltrexone, administered once monthly by a healthcare provider. The monthly injection format is clinically important for Service members: it eliminates the daily decision about whether to take the medication, reduces the impact of ambivalent days when a person might skip a dose, and creates a consistent therapeutic window. A landmark trial published in The Lancet found that extended-release naltrexone reduced opioid relapse rates by 90 percent compared to placebo during the study period.

Vivitrol is also approved for alcohol use disorder. In the alcohol context, it works by blocking the endorphin release triggered by alcohol consumption, reducing the rewarding effect of drinking and decreasing the motivation to drink. Research published in JAMA Psychiatry demonstrates that naltrexone significantly reduces heavy drinking days and increases abstinence rates in alcohol use disorder.

For veterans who have completed medical detox and are strongly motivated to maintain abstinence, Vivitrol provides a pharmacological safety net that reduces the catastrophic consequences of a moment of weakness. Hope Valley’s clinical staff evaluates each veteran’s clinical profile to determine whether Vivitrol or buprenorphine is the more appropriate MAT approach. There is no universal answer, and the decision involves the veteran’s history of prior treatment, current level of motivation, social support, and the severity and duration of their opioid dependence.

For more information on detox as the precursor to MAT, see our resource on medical detox for Veterans.

Campral (Acamprosate): Restoring Brain Chemistry After Alcohol

Acamprosate, marketed under the brand name Campral, addresses a specific neurobiological problem that emerges following prolonged heavy alcohol use: glutamate-GABA imbalance. The brain is a system in balance. Alcohol suppresses glutamate (the primary excitatory neurotransmitter) and enhances GABA (the primary inhibitory neurotransmitter). Over years of heavy drinking, the brain compensates by upregulating glutamate receptors and downregulating GABA, attempting to maintain equilibrium against the suppressive effect of alcohol.

When alcohol is removed, this compensated system is suddenly without its suppressor. The result is a brain in a hyperexcited state: anxiety, insomnia, irritability, sensory hyperactivity, and intense craving. In severe cases, glutamate excess produces seizures. This neurobiological state drives relapse not because of conscious choice, but because the brain is in a physiological emergency that alcohol temporarily resolves.

Acamprosate works by modulating glutamate and GABA systems, dampening the hyperexcited state and reducing the neurological distress that drives early-recovery relapse. It does not produce euphoria and is not addictive. It does not interact with alcohol: if a person drinks while taking it, no aversive reaction occurs (unlike disulfiram/Antabuse), but the medication continues to reduce the craving that leads to the next drink.

Meta-analyses published in JAMA confirm that acamprosate significantly increases abstinence rates and reduces relapse to heavy drinking in alcohol use disorder. For veterans with alcohol use disorder, who often have years of heavy use driven by untreated PTSD and social isolation, acamprosate addresses the biological barrier to early recovery that behavioral therapies alone cannot overcome.

Acamprosate is taken as a tablet three times daily and must be maintained consistently to be effective. Hope Valley’s clinical team monitors compliance and adjusts the treatment plan based on each veteran’s response. For veterans with both alcohol use disorder and opioid use disorder, a common co-occurring presentation, the medication protocol is coordinated to address both conditions without pharmacological conflicts.

For more information about alcohol-specific treatment for veterans, see our resource on Veteran alcohol addiction.

How MAT Works in a Veteran-Specific Residential Program

Medication-assisted treatment is most effective when embedded in a comprehensive treatment program, not administered in isolation. The medications address the biological dimension of addiction. Sustained recovery requires simultaneous work on the psychological, social, and trauma dimensions that drove substance use in the first place.

At Hope Valley Health and Wellness, MAT is integrated into a residential program designed specifically for Service members. This means:

• Psychiatric evaluation at intake: Every Service member entering the program receives a comprehensive psychiatric evaluation that includes assessment of PTSD, traumatic brain injury, depression, anxiety, and other co-occurring conditions. Medication management is coordinated across all conditions. A Veteran with PTSD and opioid use disorder may need both buprenorphine and an evidence-based PTSD medication protocol, and these interact in ways that require clinical expertise to manage safely.
• Trauma-focused therapy alongside MAT: Buprenorphine stabilizes a Veteran’s neurological state and eliminates the daily crisis of opioid seeking. This stability creates the cognitive and emotional capacity for trauma-focused therapy (EMDR, Cognitive Processing Therapy, Accelerated Resolution Therapy) that addresses the underlying PTSD and moral injury driving substance use. MAT without trauma therapy leaves the root cause untreated. Trauma therapy without MAT destabilizes Veterans who cannot maintain neurological equilibrium without pharmacological support.
• Peer community integration: Veterans on MAT participate fully in the peer community alongside Veterans using other treatment protocols. There is no separation between “medicated” and “non-medicated” program tracks. Clinical staff actively challenges stigma within the group setting, and Veterans who have successfully completed MAT-integrated treatment serve as peer mentors.
• Medical monitoring: MAT requires ongoing medical monitoring: liver function, medication blood levels, assessment of adherence, and regular clinical evaluations to determine whether the dosage is producing optimal effect. Hope Valley’s medical team manages this monitoring throughout the residential stay and coordinates transition to outpatient medical providers at discharge.
• Discharge planning for continued MAT: Stopping MAT abruptly at program discharge dramatically increases overdose risk. Hope Valley’s clinical team develops discharge plans that ensure continuity of MAT through outpatient prescribers, VA pharmacies, or community opioid treatment programs, depending on where each Veteran is returning to.

The CARF accreditation held by Hope Valley Health and Wellness requires that MAT be provided according to evidence-based clinical protocols, with appropriate medical oversight and integration into the broader treatment plan. CARF accreditation is the gold standard in addiction treatment quality assurance and is recognized by TRICARE as a credential of treatment quality.

For information about fentanyl-specific MAT considerations, see our resource on fentanyl and Veterans.

TRICARE Coverage for Medication-Assisted Treatment

TRICARE covers medication-assisted treatment for both opioid use disorder and alcohol use disorder, including all FDA-approved MAT medications: buprenorphine, methadone (through licensed opioid treatment programs), naltrexone/Vivitrol, acamprosate, and disulfiram. Coverage applies to both inpatient and outpatient MAT settings.

For buprenorphine, TRICARE covers outpatient prescriptions through TRICARE pharmacy benefits and covers buprenorphine administered as part of residential treatment. Prior authorization is required for Vivitrol injections in most TRICARE plans, but Hope Valley manages this authorization process on behalf of Veterans and their families.

Key TRICARE MAT coverage points:

• TRICARE Prime, Select, and East/West plans all cover MAT medications, though specific cost-sharing and prior authorization requirements vary by plan
• Residential treatment that includes MAT is covered under TRICARE’s inpatient behavioral health benefit when provided at an authorized facility
• TRICARE for Life (the Medicare supplement plan for Veterans with Medicare) covers MAT through Medicare Part D pharmacy benefits and Part B for some injected medications
• TRICARE Reserve Select covers MAT for National Guard and Reserve Veterans who maintain qualifying coverage

Hope Valley’s benefits team conducts a free, one-business-day verification of each Veteran’s TRICARE coverage before admission, confirming exact coverage, prior authorization requirements, and any cost-sharing obligations. Veterans and families are not expected to navigate the TRICARE prior authorization system on their own; Hope Valley manages this process as a standard part of admission.

The documented mortality benefit of MAT, more than a 50 percent reduction in overdose death rates, makes TRICARE coverage of these medications one of the highest-value interventions available under any military health benefit. For Veterans who have already lost peers to overdose, and who are managing the weight of years of untreated trauma and physical pain, MAT represents a concrete, proven path toward a stable, functional life.

For information about TRICARE coverage in Alaska more broadly, see our resource on TRICARE coverage for Alaska Veterans.